Foghorn Therapeutics, Inc.

As of March 10, 2022, Foghorn Therapeutics, Inc. is considered a risky investment due to its negative valuation ratios and overvaluation compared to peers, with a current price of 5.14.

Foghorn Therapeutics, Inc. is currently considered a risky investment due to its overvaluation and negative financial ratios, including a Price to Book Value of -4.03, and has underperformed with a 7.74% decline in stock price over the past year.

As of May 2, 2025, Foghorn Therapeutics, Inc. shows a mildly bearish trend due to daily moving averages indicating bearishness, while weekly indicators suggest mild bullishness, resulting in mixed signals and a lack of strong momentum.

As of March 2022, the management team of Foghorn Therapeutics, Inc. includes Mr. Douglas Cole as Chairman of the Board and founder, and Mr. Adrian Gottschalk as President, CEO, and Director.

Foghorn Therapeutics, Inc. develops medicines targeting genetic dependencies in the chromatin regulatory system, with a market cap of $267 million and recent net sales of $6 million but a net loss of $19 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap firm.

As of Jun 18, Foghorn Therapeutics, Inc. has a market capitalization of 267.00 million and reported net sales of 23.51 million with a net profit of -80.43 million over the last four quarters. Shareholder's funds are at -45.53 million, and total assets amount to 458.37 million.